Comparison of Intralesional Triamcinolone Acetonide Treatment With Intralesional Verapamil Hydrochloride in Keloids

NCT07420166 | Completed

• 1 other identifier: Dr-Bakhtawar-BVH
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The paucity of local literature regarding the comparison of intralesional verapamil with intralesional triamcinolone acetonide led this study to be carried out with the objective of comparing the clinical effectiveness of intralesional triamcinolone acetonide and intralesional verapamil hydrochloride in patients with keloids.

Conditions

Keloid

Outcome Measures

Primary Outcomes (1)

• Scar assessment

  Using the Vancouver Scar Scale, height, vascularity, pliability, and pigmentation were assessed at baseline and compared with post-treatment measures at 24 weeks. A score closer to 0 was deemed as better vascularity (not red), low pigmentation, high pliability (soft), and low thickness.

  24 weeks

Study Arms (2)

Triamcinolone Group

EXPERIMENTAL

Patients received intralesional triamcinolone acetonide (20 mg/mL) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion.

Drug: Triamcinolone Acetonide

Verapamil Group

EXPERIMENTAL

Patients were managed with intralesional verapamil hydrochloride (2.5 mg/ml) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion.

Drug: Verapamil Hydrochloride

Interventions

Triamcinolone Acetonide DRUG

Patients received intralesional triamcinolone acetonide (20 mg/ml) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion.

Triamcinolone Group

Verapamil Hydrochloride DRUG

Patients were managed with intralesional verapamil hydrochloride (2.5 mg/ml) at a volume not exceeding 1.5 cc per session every three weeks, for a maximum of eight sessions or until complete scar flattening. Each injection session was preceded by 20 seconds of cryotherapy using cryospray applied at a distance of one centimeter from the lesion.

Verapamil Group

Eligibility Criteria

• Age: 20 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Either gender
• Aged between 20 and 60 years
• With keloids
• Benign dermal growths
• Scar length not exceeding 5 centimeters
• Keloid duration of five years or less
• A baseline Vancouver Scar Scale score of 5 or more

You may not qualify if:

• Pregnant or lactating women
• A family history of keloids
• Diagnosed with conditions such as acromegaly, diabetes mellitus, or congestive cardiac disease
• a history of thyroidectomy
• Current or recent use of isotretinoin or anabolic steroids, as determined by history, physical examination, blood glucose analysis, and electrocardiography

Sponsors & Collaborators

• Muhammad Aamir Latif: lead

Study Sites (1)

Bahawal Victoria Hospital/Quaid-e-Azam Medical College

Bahawalpur, Punjab Province, 63100, Pakistan

Location

MeSH Terms

Conditions

Keloid

Interventions

Triamcinolone Acetonide; Verapamil

Condition Hierarchy (Ancestors)

Collagen Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Cicatrix; Fibrosis; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Triamcinolone; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Steroids, Fluorinated; Phenethylamines; Ethylamines; Amines; Organic Chemicals

Study Officials

• Bakhtawar

  Bahawal Victoria Hospital/Quaid-e-Azam Medical College, Bahawalpur

  PRINCIPAL INVESTIGATOR

• Salman Ashraf, FCPS

  Bahawal Victoria Hospital/Quaid-e-Azam Medical College, Bahawalpur

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Research Consultant

Study Record Dates

• First Submitted: February 12, 2026
• First Posted: February 19, 2026
• Study Start: January 1, 2025
• Primary Completion: June 30, 2025
• Study Completion: June 30, 2025
• Last Updated: February 19, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)